For parents: Not sure what axial length numbers mean? Start with a simple explanation →

MiSight® vs Stellest® — Myopia Control Efficacy Comparison

MiSight® 1 day (CooperVision) and Stellest® HALT lenses (EssilorLuxottica) represent two of the most evidence-supported optical interventions for myopia control in children. Both have high-quality RCT data, but their mechanisms, patient profiles, and practical considerations differ meaningfully.

Efficacy Data at a Glance

Metric	MiSight® 1 day	Stellest® (HALT)
AL reduction vs untreated	55%	67%
Primary RCT	Chamberlain et al. 2019	Bao et al. 2022
Journal	Optometry & Vision Science	JAMA Ophthalmology
Study duration	3 years	2 years
Modality	Soft daily disposable contact lens	Spectacle lens (HALT design)
Minimum age (typical)	8 years	6 years
Compliance dependency	High (contact lens wear hours)	Moderate (spectacle wear hours)

2026 update: A U.S. randomized HAL spectacle-lens trial in children aged 6–12 adds important domestic evidence for the spectacle-lens category. It should be interpreted by age range, baseline refractive range, comparator, duration, and axial-length endpoint — not as a universal replacement for patient-specific clinical judgment.

Mechanism

MiSight® 1 day uses a dual-focus design with alternating distance correction zones and treatment (myopic defocus) zones. The treatment zones create simultaneous myopic defocus across the peripheral retina, which is hypothesized to slow the scleral growth signal driving axial elongation.

Stellest® HALT (Highly Aspherical Lenslet Target) creates a volume of myopic defocus in front of the retina using 11 rings of non-contiguous aspherical lenslets. Unlike MiSight, the lenslets create a conical volume of focus rather than discrete rings, covering a broader area of the retinal periphery.

Clinical Considerations

Choose MiSight® when: The child is suitable for contact lens wear (typically 8+), has good hygiene habits and parental support for daily lens care, and the family prefers daily disposables over spectacles.

Choose Stellest® when: The child is too young for contact lenses (under 8), contact lens tolerance is poor, compliance with lens care is a concern, or spectacle wear is preferred for simplicity.

Both are appropriate as monotherapy for moderate progressors. For high-risk patients (AL >95th percentile, growth rate >0.40mm/year (a commonly used clinical trigger; not a formal IMI 2025 guideline cutoff), young age of onset), combination therapy with low-dose atropine may provide additional benefit beyond either modality alone.

Evidence Applicability Checklist

Before applying any treatment study to an individual child, check whether the evidence resembles the patient in front of you.

Age match: Most pivotal optical trials are pediatric; adult and young-adult evidence remains less mature.
Baseline myopia match: Mild-to-moderate trial cohorts may not predict response in very high myopia.
Endpoint match: Axial length is the key structural endpoint; SER alone can miss biologic progression.
Follow-up match: Six-month findings are useful, but multi-year results are stronger for counseling.
Availability match: Product labeling and regulatory status vary by country.

Project the Outcome for Your Patient

MyopiaTracker allows you to input your patient's age, current axial length, and prior AL to generate a projected outcome with MiSight®, Stellest®, and all other modalities side by side — using the RCT efficacy values above. Free preview; Pro trial required for saving and reports.

Try the tool for your patients

Preview axial-length risk, then start a Pro trial to save patients, compare treatments, and generate parent-ready reports.

Start 14-day Pro trial →

This page is provided for educational purposes. MyopiaTracker is a clinical decision support tool and does not constitute medical advice, diagnosis, or treatment. All efficacy values are population averages from published RCTs; individual patient outcomes vary. MiSight® is a registered trademark of The Cooper Companies, Inc. Stellest® is a registered trademark of Essilor International. MiyoSmart® is a registered trademark of Hoya Corporation. Sources include Chamberlain et al. 2019, Bao et al. 2022, and the 2026 U.S. HAL spectacle-lens randomized trial in JAMA Ophthalmology.